Predictors of Severe Haematological Toxicity Secondary to Pegylated Interferon plus Ribavirin Treatment in HIV-HCV-Coinfected Patients
- 1 November 2007
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 12 (8) , 1225-1236
Abstract
Background: Haematological adverse events related to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy could affect the patients’ quality of life; however, the risk factors for severe haematological toxicity associated with this therapy in patients coinfected with hepatitis C virus (HCV) and HIV are unclear. The objective of this study was to identify predictors of severe haematological toxicity among HIV-HCV-coinfected patients treated with PEG-IFN plus RBV. Methods: This retrospective multicentric study included 237 HIV-HCV-coinfected patients on PEG-IFN plus RBV. Predictors of severe anaemia, neutropenia, thrombocytopenia and overall haematological toxicity were analyzed. Results: Eighty (34%) individuals showed an episode of severe haematological toxicity. Severe anaemia, neutropenia and thrombocytopenia occurred in 32 (13%), 42 (18%) and 26 (11%) patients, respectively. In the multivariate analysis, zidovudine use (adjusted odds ratio [AOR] 3.3; 95% confidence interval [CI] 1.6–10; P=0.001), baseline body weight 3 and platelet counts 3 were independent predictors of severe anaemia, neutropenia and thrombocytopenia, respectively. Conclusions: Zidovudine treatment, cirrhosis, baseline low body weight, use of PEG-IFN-α2a, and baseline haemoglobin level <14 g/dl are predictors of overall severe haematological toxicity secondary to PEG-IFN plus RBV in HIV-infected individuals. Low pretreatment levels of each haematological series predict a significant decrease of their values during therapy.Keywords
This publication has 29 references indexed in Scilit:
- Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International PanelAIDS, 2007
- Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment responseLiver International, 2006
- Predictors for Hematopoietic Growth Factors Use in HIV/HCV-Coinfected Patients Treated with Peginterferon Alfa 2b and RibavirinAIDS Patient Care and STDs, 2006
- Zidovudine use but not weight‐based ribavirin dosing impacts anaemia during HCV treatment in HIV‐infected personsJournal of Viral Hepatitis, 2006
- A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)Journal of Hepatology, 2006
- Rate of Infectious Complications during Interferon-Based Therapy for Hepatitis C Is Not Related to NeutropeniaClinical Infectious Diseases, 2006
- Antiviral hepatitis and antiretroviral drug interactionsJournal of Hepatology, 2005
- Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon α mono and combination therapy regimensGut, 2005
- Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirinHepatology, 2004
- Classification of chronic viral hepatitis: a need for reassessmentJournal of Hepatology, 1991